Cargando…
Adverse effects of gender‐affirming hormonal therapy in transgender persons: Assessing reports in the French pharmacovigilance database
Limited data are available on adverse drug reactions (ADRs) of gender‐affirming hormone therapy (HT), mainly due to the lack of population‐based studies with adequate controls, thus making spontaneous reporting systems a valuable tool to detect potential side reactions. In this nationwide retrospect...
Autores principales: | Yelehe, Melissa, Klein, Marc, El Aridi, Layal, Maurier, Anaïs, Gillet, Pierre, Feigerlova, Eva |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796635/ https://www.ncbi.nlm.nih.gov/pubmed/35653182 http://dx.doi.org/10.1111/fcp.12806 |
Ejemplares similares
-
Immune check point inhibitors-induced hypophysitis: a retrospective analysis of the French Pharmacovigilance database
por: Garon-Czmil, Julie, et al.
Publicado: (2019) -
Clinical pearls of gender-affirming hormone therapy in transgender patients
por: Irving, Amanda, et al.
Publicado: (2018) -
Gender-affirming Hormone Therapy and Risk of Diabetes in Transgender Persons
por: Tangpricha, Vin
Publicado: (2022) -
Cardiovascular Risk in Transgender People With Gender-Affirming Hormone Treatment
por: Masumori, Naoya, et al.
Publicado: (2023) -
Cardiovascular Risk Associated With Gender Affirming Hormone Therapy in Transgender Population
por: Aranda, Gloria, et al.
Publicado: (2021)